<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment
Image Overlay - Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

December 3, 2020

Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

Parexel Biotech has entered into a strategic collaboration with Synairgen. The two companies are working together on a phase III study of SNG001, an inhaled treatment for patients hospitalized with COVID-19. The trial aims to enroll 900 patients across 20 countries. Yourway has 21 strategically located depots around the world, to help advance all trials, at any scale, everywhere.

Back to Index
Media

Upcoming Events

42nd Annual J.P. Morgan Healthcare Conference

January 8-11, 2024
San Francisco, CA

Media

Articles

Helping Sponsors Navigate Complex Ancillary Supply Sourcing Challenges with Integrated Services

Open chat
Come chat with us!
Hello! How can I help you?